114P Folate receptor alpha expression in high-grade serous ovarian cancer: Association with sampling variables, homologous recombination deficiency and platinum-free interval

Folate receptor alpha (FRα)-targeted antibody-drug conjugates are approved in platinum-resistant high-grade serous ovarian cancer (HGSOC) and are being explored in multiple clinical settings. The full clinical significance of FRα expression remains unclear: whether it varies by sample timing or type, overlaps with homologous recombination deficiency (HRD), or influences platinum sensitivity, with implications for biomarker-driven patient selection.